Literature DB >> 21779515

Li-fraumeni syndrome.

David Malkin1.   

Abstract

Li-Fraumeni syndrome (LFS) is a classic cancer predisposition disorder that is commonly associated with germline mutations of the p53 tumor suppressor gene. Examination of the wide spectrum of adult-onset and childhood cancers and the distribution of p53 mutations has led to a greater understanding of cancer genotype-phenotype correlations. However, the complex LFS phenotype is not readily explained by the simple identification of germline p53 mutations in affected individuals. Recent work has identified genetic events that modify the LFS phenotype. These include intragenic polymorphisms, mutations/polymorphisms of genes in the p53 regulatory pathway, as well as more global events such as aberrant copy number variation and telomere attrition. These genetic events may, in part, explain the breadth of tumor histiotypes within and across LFS families, the apparent accelerated age of onset within families, and the range of clinical outcomes among affected family members. This review will examine the clinical and genetic definitions of LFS and offer insight into how lessons learned from the study of this rare disorder may inform similar questions in other familial cancer syndromes.

Entities:  

Keywords:  Li-Fraumeni syndrome; cancer predisposition; germline p53 mutations

Year:  2011        PMID: 21779515      PMCID: PMC3135649          DOI: 10.1177/1947601911413466

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  95 in total

1.  Screening hCHK2 for mutations.

Authors:  N Sodha; R Williams; J Mangion; S L Bullock; M R Yuille; R A Eeles
Journal:  Science       Date:  2000-07-21       Impact factor: 47.728

2.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

4.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

5.  Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.

Authors:  Sonia Garritano; Federica Gemignani; Edenir Inez Palmero; Magali Olivier; Ghyslaine Martel-Planche; Florence Le Calvez-Kelm; Laurence Brugiéres; Fernando Regla Vargas; Ricardo Renzo Brentani; Patricia Ashton-Prolla; Stefano Landi; Sean V Tavtigian; Pierre Hainaut; Maria Isabel W Achatz
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

6.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

7.  Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.

Authors:  Marie Trkova; Kamila Prochazkova; Vera Krutilkova; David Sumerauer; Zdenek Sedlacek
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

8.  Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.

Authors:  Sang Mee Hwang; Eun Sook Lee; Sang Hoon Shin; Sun-Young Kong
Journal:  Korean J Lab Med       Date:  2008-12

9.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  147 in total

1.  Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.

Authors:  Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

2.  The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Authors:  Madison Miller; Nitin Shirole; Ruxiao Tian; Debjani Pal; Raffaella Sordella
Journal:  J Cancer Biol Res       Date:  2016-12-23

3.  Introduction: The Changing Directions of p53 Research.

Authors:  Arnold J Levine
Journal:  Genes Cancer       Date:  2011-04

4.  Ovarian and uterine cancer incidence and mortality in American Indian and Alaska Native women, United States, 1999-2009.

Authors:  Simple D Singh; A Blythe Ryerson; Manxia Wu; Judith S Kaur
Journal:  Am J Public Health       Date:  2014-04-22       Impact factor: 9.308

Review 5.  Genetic and nongenetic risk factors for childhood cancer.

Authors:  Logan G Spector; Nathan Pankratz; Erin L Marcotte
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

6.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

7.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

8.  Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.

Authors:  Francesca Ponti; Serena Corsini; Maria Gnoli; Elena Pedrini; Marina Mordenti; Luca Sangiorgi
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

9.  Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours.

Authors:  Juliette Aury-Landas; Gaëlle Bougeard; Hélène Castel; Hector Hernandez-Vargas; Aurélie Drouet; Jean-Baptiste Latouche; Marie-Thérèse Schouft; Claude Férec; Dominique Leroux; Christine Lasset; Isabelle Coupier; Olivier Caron; Zdenko Herceg; Thierry Frebourg; Jean-Michel Flaman
Journal:  Eur J Hum Genet       Date:  2013-04-24       Impact factor: 4.246

10.  Detecting statistical interaction between somatic mutational events and germline variation from next-generation sequence data.

Authors:  Hao Hu; Chad D Huff
Journal:  Pac Symp Biocomput       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.